These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 33070172)

  • 21. Loss of PTEN attenuates the development of pathological hypertrophy and heart failure in response to biomechanical stress.
    Oudit GY; Kassiri Z; Zhou J; Liu QC; Liu PP; Backx PH; Dawood F; Crackower MA; Scholey JW; Penninger JM
    Cardiovasc Res; 2008 Jun; 78(3):505-14. PubMed ID: 18281373
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Choline ameliorates cardiac hypertrophy by regulating metabolic remodelling and UPRmt through SIRT3-AMPK pathway.
    Xu M; Xue RQ; Lu Y; Yong SY; Wu Q; Cui YL; Zuo XT; Yu XJ; Zhao M; Zang WJ
    Cardiovasc Res; 2019 Mar; 115(3):530-545. PubMed ID: 30165480
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiac Stim1 Silencing Impairs Adaptive Hypertrophy and Promotes Heart Failure Through Inactivation of mTORC2/Akt Signaling.
    Bénard L; Oh JG; Cacheux M; Lee A; Nonnenmacher M; Matasic DS; Kohlbrenner E; Kho C; Pavoine C; Hajjar RJ; Hulot JS
    Circulation; 2016 Apr; 133(15):1458-71; discussion 1471. PubMed ID: 26936863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased ketone body oxidation provides additional energy for the failing heart without improving cardiac efficiency.
    Ho KL; Zhang L; Wagg C; Al Batran R; Gopal K; Levasseur J; Leone T; Dyck JRB; Ussher JR; Muoio DM; Kelly DP; Lopaschuk GD
    Cardiovasc Res; 2019 Sep; 115(11):1606-1616. PubMed ID: 30778524
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peroxiredoxin-1 ameliorates pressure overload-induced cardiac hypertrophy and fibrosis.
    Tang C; Yin G; Huang C; Wang H; Gao J; Luo J; Zhang Z; Wang J; Hong J; Chai X
    Biomed Pharmacother; 2020 Sep; 129():110357. PubMed ID: 32531679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AAV-mediated expression of NFAT decoy oligonucleotides protects from cardiac hypertrophy and heart failure.
    Remes A; Wagner AH; Schmiedel N; Heckmann M; Ruf T; Ding L; Jungmann A; Senger F; Katus HA; Ullrich ND; Frey N; Hecker M; Müller OJ
    Basic Res Cardiol; 2021 Jun; 116(1):38. PubMed ID: 34089101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Partial Liver Kinase B1 (LKB1) Deficiency Promotes Diastolic Dysfunction, De Novo Systolic Dysfunction, Apoptosis, and Mitochondrial Dysfunction With Dietary Metabolic Challenge.
    Miller EJ; Calamaras T; Elezaby A; Sverdlov A; Qin F; Luptak I; Wang K; Sun X; Vijay A; Croteau D; Bachschmid M; Cohen RA; Walsh K; Colucci WS
    J Am Heart Assoc; 2015 Dec; 5(1):. PubMed ID: 26722122
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Loss of the eukaryotic initiation factor 2α kinase general control nonderepressible 2 protects mice from pressure overload-induced congestive heart failure without affecting ventricular hypertrophy.
    Lu Z; Xu X; Fassett J; Kwak D; Liu X; Hu X; Wang H; Guo H; Xu D; Yan S; McFalls EO; Lu F; Bache RJ; Chen Y
    Hypertension; 2014 Jan; 63(1):128-35. PubMed ID: 24166753
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phosphoinositide 3-kinase p110α is a master regulator of exercise-induced cardioprotection and PI3K gene therapy rescues cardiac dysfunction.
    Weeks KL; Gao X; Du XJ; Boey EJ; Matsumoto A; Bernardo BC; Kiriazis H; Cemerlang N; Tan JW; Tham YK; Franke TF; Qian H; Bogoyevitch MA; Woodcock EA; Febbraio MA; Gregorevic P; McMullen JR
    Circ Heart Fail; 2012 Jul; 5(4):523-34. PubMed ID: 22705768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quercetin Prevents In Vivo and In Vitro Myocardial Hypertrophy Through the Proteasome-GSK-3 Pathway.
    Chen K; Rekep M; Wei W; Wu Q; Xue Q; Li S; Tian J; Yi Q; Zhang G; Zhang G; Xiao Q; Luo J; Liu Y
    Cardiovasc Drugs Ther; 2018 Feb; 32(1):5-21. PubMed ID: 29435775
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protection against pressure overload-induced right heart failure by uncoupling protein 2 silencing.
    Esfandiary A; Kutsche HS; Schreckenberg R; Weber M; Pak O; Kojonazarov B; Sydykov A; Hirschhäuser C; Wolf A; Haag D; Hecker M; Fink L; Seeger W; Ghofrani HA; Schermuly RT; Weißmann N; Schulz R; Rohrbach S; Li L; Sommer N; Schlüter KD
    Cardiovasc Res; 2019 Jun; 115(7):1217-1227. PubMed ID: 30850841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Double-stranded RNA-dependent protein kinase deficiency protects the heart from systolic overload-induced congestive heart failure.
    Wang H; Xu X; Fassett J; Kwak D; Liu X; Hu X; Falls TJ; Bell JC; Li H; Bitterman P; Bache RJ; Chen Y
    Circulation; 2014 Apr; 129(13):1397-406. PubMed ID: 24463368
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Downregulation of survival signalling pathways and increased apoptosis in the transition of pressure overload-induced cardiac hypertrophy to heart failure.
    Li XM; Ma YT; Yang YN; Liu F; Chen BD; Han W; Zhang JF; Gao XM
    Clin Exp Pharmacol Physiol; 2009 Nov; 36(11):1054-61. PubMed ID: 19566828
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FABP5 Deficiency Impairs Mitochondrial Function and Aggravates Pathological Cardiac Remodeling and Dysfunction.
    Gao S; Li G; Shao Y; Wei Z; Huang S; Qi F; Jiao Y; Li Y; Zhang C; Du J
    Cardiovasc Toxicol; 2021 Aug; 21(8):619-629. PubMed ID: 33929718
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overexpression of A kinase interacting protein 1 attenuates myocardial ischaemia/reperfusion injury but does not influence heart failure development.
    Booij HG; Yu H; De Boer RA; van de Kolk CW; van de Sluis B; Van Deursen JM; Van Gilst WH; Silljé HH; Westenbrink BD
    Cardiovasc Res; 2016 Aug; 111(3):217-26. PubMed ID: 27302402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Toll-like receptor-2 mediates adaptive cardiac hypertrophy in response to pressure overload through interleukin-1β upregulation via nuclear factor κB activation.
    Higashikuni Y; Tanaka K; Kato M; Nureki O; Hirata Y; Nagai R; Komuro I; Sata M
    J Am Heart Assoc; 2013 Nov; 2(6):e000267. PubMed ID: 24249711
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronically Elevating Circulating Ketones Can Reduce Cardiac Inflammation and Blunt the Development of Heart Failure.
    Byrne NJ; Soni S; Takahara S; Ferdaoussi M; Al Batran R; Darwesh AM; Levasseur JL; Beker D; Vos DY; Schmidt MA; Alam AS; Maayah ZH; Schertzer JD; Seubert JM; Ussher JR; Dyck JRB
    Circ Heart Fail; 2020 Jun; 13(6):e006573. PubMed ID: 32493060
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A cathelicidin-related antimicrobial peptide suppresses cardiac hypertrophy induced by pressure overload by regulating IGFR1/PI3K/AKT and TLR9/AMPKα.
    Wang X; Chen L; Zhao X; Xiao L; Yi S; Kong Y; Jiang Y; Zhang J
    Cell Death Dis; 2020 Feb; 11(2):96. PubMed ID: 32029708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Short-term but not long-term high fat diet feeding protects against pressure overload-induced heart failure through activation of mitophagy.
    Tan Y; Li M; Wu G; Lou J; Feng M; Xu J; Zhou J; Zhang P; Yang H; Dong L; Li J; Zhang X; Gao F
    Life Sci; 2021 May; 272():119242. PubMed ID: 33607155
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antagonizing the CX3CR1 Receptor Markedly Reduces Development of Cardiac Hypertrophy After Transverse Aortic Constriction in Mice.
    Nemska S; Gassmann M; Bang ML; Frossard N; Tavakoli R
    J Cardiovasc Pharmacol; 2021 Dec; 78(6):792-801. PubMed ID: 34882111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.